Skip to main content
SpringerLink
Log in
Book cover

Antitumor Antibiotics pp 148–151Cite as

Mitomycin C: Experience in the United States, with Emphasis on Gastric Cancer

  • Chapter

  • 135 Accesses

Abstract

Mitomycin C is an antibiotic alkylating agent isolated from the fermentation of Streptomyces caespitosus in 1958. Clinical trials were initiated in Japan soon after the demonstration of antitumor activity against a broad spectrum of transplanted animal tumours [2]. Mitomycin C was reported to have a high degree of efficacy for human cancer, which prompted a cooperative multiinstitution evaluation of this agent in the United States. A preliminary summary of the results of the initial experience was reported in 1959 by Jones [11]. Of 120 patients treated, objective responses were observed in 21 (18.5%) including breast cancer, Hodgkin’s disease, lymphocytic lymphoma and chronic granulocytic leukemia. Treatment was discontinued in 87% of patients because of severe hematologic toxicity. It was concluded that mitomycin C had an extremely narrow therapeutic index, while demonstrating only limited efficacy. The result was a sharply reduced interest for mitomycin C as an anticancer agent in the United States.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Baker, L. H., Caoili, E. M., Izbicki, R. M., Opipari, M. I., Vaitkevicius, V. K.: A comparative study of mitomycin C and porfiromycin. Proc. Am. Soc. Clin. Oncol. 15, 182(1974).

    Google Scholar 

  2. Carter, S. K.: Mitomycin C (NSC-26980) clinical brochure. Cancer Chemother. Rep., part 3 1, 99–114(1968).

    CAS  Google Scholar 

  3. Comis, R. L., Carter, S. K.: Integration of chemotherapy into combined modality treatment of solid tumors III. Gastric cancer. Cancer Treat. Rev. 1, 221–238 (1974).

    Google Scholar 

  4. Crooke, S. T., Bradner, W. T.: Mitomycin C.: A review. Cancer Treat. Rev. 3, 121 139, 1976.

    Google Scholar 

  5. Dejager, R. L., Magill, G. B., Golbey, R. B., Krakoff, I. H.: Combination chemotherapy with mitomycin C, 5-fluorouracil, and cytosine arabinoside in gastrointestinal cancer. Cancer Treat. Rep. 60,1373–1375(1976).

    PubMed  Google Scholar 

  6. Ferguson, D., Humphrey, E.: Mitomycin C. Cancer Chemother. Rep. 8, 154 (1960).

    Google Scholar 

  7. Frank, W., Osterberg, A. E.: Mitomycin C (NSC-26980), an evaluation of Japanese reports. Cancer Chemother. Rep. 9, 114–119 (1960).

    PubMed  CAS  Google Scholar 

  8. Godfrey, T. E., Wilbur, D. W.: Clinical experience with mitomycin C in large infrequent doses. Cancer 29, 1647–1652(1972).

    Article  PubMed  Google Scholar 

  9. Horton, J., Olson, K. B., Gehrt, P., Spear, M.: Combination therapy with 5-fluorouracil (NSC-19893), mitomycin (NSC-26980), vincristine (NSC-67574), and thioTEPA (NSC-6396) for advanced cancer. Cancer Chemother. Rep. 49, 59–61 (1965).

    PubMed  CAS  Google Scholar 

  10. Hoshino, A., Kato, T., Amo, H., et al.: Combination chemotherapy of mitomycin C, 5-fluorouracil and cytosine arabinoside in L-1210 mouse leukemia. In: Proceedings of the 10th International Cancer Congress, Houston, Texas. Houston: Medical Arts Publishing Co. 1970, pp 409–410.

    Google Scholar 

  11. Jones, R. Jr.: Mitomycin C. A preliminary report of studies of human pharmacology and initial therapeutic trial. Cancer Chemother. Rep. 2, 3–7 (1959).

    Google Scholar 

  12. Liu, K., Mittleman, A., Sproul, E. E., Elias, E. G.: Renal toxicity in man treated with mitomyein-C. Cancer 28, 1314–1320(1971).

    Article  Google Scholar 

  13. Macdonald, J., Schein, P., Ueno, W., Woolley, P.: 5-Fluorouracil, mitomycin C, and adriamycin—F AM: A new combination chemotherapy program for advanced gastric carcinoma. Proc. Am. Soc. Clin. Onc. 17, 264 (1976).

    Google Scholar 

  14. Manheiner, L. H., Vital, J.: Mitomycin-C in the therapy of far-advanced malignant tumors. Cancer 19, 207–212 (1966).

    Article  Google Scholar 

  15. Moertel, C. G., Reitemeier, R. J., Hahn, R. G.: Mitomycin C therapy in advanced gastrointestinal cancer. J. Am. Med. Assoc. 204, 1045–1048 (1968).

    Article  CAS  Google Scholar 

  16. Moore, G. E., Boss, I. D. J., Ausman, R., Nadler, S., Jones, R., Jr., Slack, N., Rimm, A. A.: Effects of mitomycin C. (NSC-26980) in 346 patients with advanced cancer. Eastern clinical drug evaluation program. Cancer Chemother. Rep. 52, 657–684 (1968).

    Google Scholar 

  17. Ota, K., Kurita, S., Nishimura, M., et al.: Combination therapy with mitomycin-C (NSC-26980), 5-fluorouracil (NSC-19883), and cytosine arabinoside (NSC-63878) for advanced cancer in man. Cancer Chemotherap. Rep. 56, 373–385 (1972).

    CAS  Google Scholar 

  18. Ratanatharathorn, V., Cadnapaphorndai, P., Rosenberg, B., Baker, L. H., Taber, S., Ruffer, B. W., Mcdonald, F. D., Vaitkevicius, V. K.: Clinicai and pathologic study of mitomycin-C nephrotoxicity: A retrospective analysis. Proc. Am. Soc. Clin. Oncology 18, 293 (1977).

    Google Scholar 

  19. Reitemeier, R. J., Moertel, C. G., Hahn, R. G.: Combination chemotherapy in gastrointestinal cancer. Cancer Chemother. Rep. 30, 1425–1428 (1970).

    CAS  Google Scholar 

  20. Wiggans, G., Smythe, T., Ueno, W., Macdonald, J., Schein, P., Flannery, E.: Streptozotocin, mitomycin, and 5-fluorouracil, SMF, chemotherapy for advanced pancreatic carcinoma: Phase II trial. Cancer (In Press).

    Google Scholar 

Download references

Authors
  1. P. S. Schein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. S. MacDonald
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Hoth
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. V. Woolley
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Northern California Cancer Program, 1801 Page Mill Road, Bldg. B, Suite 200, Palo Alto, California, 94304, USA

    S. K. Carter (Director) (Director)

  2. Department of Antibiotics, National Institutes of Health, Kami-Osaki 2-10-35, Shinagawa-ku, Tokyo, 1411, Japan

    Hamao Umezawa (Head) (Head)

  3. Division of Cancer Treatment, National Cancer Institute, Blair Bldg. Room 4A15, 8300 Colesville Road, Silver Spring, Maryland, 20910, USA

    John Douros

  4. Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Kami-Ikebukuro 1-37-1, Toshima-ku, Tokyo, Japan

    Yoshio Sakurai (Director) (Director)

Rights and permissions

Reprints and permissions

Copyright information

© 1978 Springer-Verlag Berlin · Heidelberg

About this chapter

Cite this chapter

Schein, P.S., MacDonald, J.S., Hoth, D., Woolley, P.V. (1978). Mitomycin C: Experience in the United States, with Emphasis on Gastric Cancer. In: Carter, S.K., Umezawa, H., Douros, J., Sakurai, Y. (eds) Antitumor Antibiotics. Recent Results in Cancer Research / Fortschritte der Krebsforschung / Progrès dans les recherches sur le cancer, vol 63. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81219-4_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-81219-4_14

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-81221-7

  • Online ISBN: 978-3-642-81219-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation